ReviewPigment cell & melanoma research2021
Emerging strategies to treat rare and intractable subtypes of melanoma.
Review in Pigment cell & melanoma research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Nanocarriers for siRNA Delivery Aimed at the Treatment of Melanoma: Systematic Review.Current drug delivery · 2025Pooled it
- Systematic review and meta-analysis of genomic alterations in acral melanoma.Pigment cell & melanoma research · 2022Pooled it
- Melanoma treatment in the era of nanotechnology and precision medicine.Journal of nanobiotechnology · 2025Review
- Targeting Melanoma Cell Adhesion Molecule as a Novel Therapeutic Approach for Acral Melanoma.Experimental dermatology · 2025Article
- Combination Immunotherapy for Mucosal Melanoma: Molecular Mechanism, Research Status, and Future Directions.Current treatment options in oncology · 2025Review
- Classification of Cutaneous Melanoma and Melanocytic Nevi with MicroRNA Ratios Is Preserved in the Acral Melanoma Subtype.The Journal of investigative dermatology · 2025Article
- Spatial sequencing reveals transcriptional variation between amelanotic and pigmented acral melanoma.The British journal of dermatology · 2024Article
- Determinants of resistance and response to melanoma therapy.Nature cancer · 2024Review
- Review
- Unaddressed Challenges in the Treatment of Cutaneous Melanoma?Medicina (Kaunas, Lithuania) · 2024Review
- Progress in melanoma treatment: Patient's perspectives.Pigment cell & melanoma research · 2023Article
- Combinations of EGFR and MET inhibitors reduce proliferation and invasiveness of mucosal melanoma cells.Journal of cellular and molecular medicine · 2023Article
- BRAF Mutations in Melanoma: Biological Aspects, Therapeutic Implications, and Circulating Biomarkers.Cancers · 2023Review
- Management of Advanced Invasive Melanoma: New Strategies.Advances in therapy · 2023Review
- Experimental Models for Rare Melanoma Research-The Niche That Needs to Be Addressed.Bioengineering (Basel, Switzerland) · 2023Review
- Integrin Targeting Enhances the Antimelanoma Effect of Annexin V in Mice.International journal of molecular sciences · 2023Article
- Human epidermal growth factor receptor 3 serves as a novel therapeutic target for acral melanoma.Cell death discovery · 2023Article
- Un-Fair Skin: racial disparities in acral melanoma research.Nature reviews. Cancer · 2022Article
- RAS pathway regulation in melanoma.Disease models & mechanisms · 2022Review
- Metabolic Alterations and Therapeutic Opportunities in Rare Forms of Melanoma.Trends in cancer · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Melanoma is the deadliest form of skin cancer, possessing a diverse landscape of subtypes with distinct molecular signatures and levels of aggressiveness. Although immense progress has been achieved therapeutically for patients with the most common forms of this disease, little is known of how to effectively treat patients with rarer subtypes of melanoma. These subtypes include acral lentiginous (the rarest form of cutaneous melanoma; AL), uveal, and mucosal melanomas, which display variations in distribution across (a) the world, (b) patient age-groups, and (c) anatomic sites. Unfortunately, patients with these relatively rare subtypes of melanoma typically respond worse to therapies approved for the more common, non-AL cutaneous melanoma and do not have effective alternatives, and thus consequently have worse overall survival rates. Achieving durable therapeutic responses in these high-risk melanoma subtypes represents one of the greatest challenges of the field. This review aims to collate and highlight effective preclinical and/or clinical strategies against these rare forms of melanoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.